Clinical trialsCompany release

Citius Oncology reports exploratory quality-of-life data for Lymphir from pivotal Study 302

🇺🇸 Citius Oncology, Inc. (CTOR) · Wed 04 Nov 2026

Patient-reported results in relapsed or refractory cutaneous T-cell lymphoma point to sustained improvements among responders, though the analyses were descriptive and sit outside the US label.

Citius Oncology announced on 4 November 2026 exploratory patient-reported quality-of-life data from Study 302, the pivotal trial of Lymphir (denileukin diftitox-cxdl) in relapsed or refractory cutaneous T-cell lymphoma (CTCL).

The data were given as an oral presentation at the annual meeting of the EORTC Cutaneous Lymphoma Tumours Group (EORTC-CLTG) in Berlin, held on 8–10 October 2026.

According to the company, patients who responded to treatment reported sustained improvements in both skin-related and overall quality of life. Among patients who had significant itch at baseline, 32% experienced a clinically meaningful reduction in itch.

Citius stressed the limits of the findings. The analyses were descriptive, Study 302 was not powered to test these outcomes, and the results do not appear in the FDA-approved prescribing information for Lymphir.

What it means for your team

  • The quality-of-life findings are exploratory and descriptive, so they should not be read as confirmatory evidence or as label claims.
  • Because the results are absent from the FDA-approved prescribing information, promotional and medical-information teams should keep them clear of on-label messaging.
  • Market-access teams may find patient-reported itch and skin-related outcomes useful context in CTCL discussions, but the lack of statistical powering limits their weight.

Company's press release (SEC filing): Citius Oncology, Inc. ↗

Article written by VigiEye from the official source (Citius Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →